Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 103, Issue 2, Pages 210-216Publisher
WILEY
DOI: 10.1002/cpt.911
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)
- NIH [R24GM115264]
- PharmGKB [R24GM61374]
- Robert Bosch Foundation, Stuttgart, Germany
Ask authors/readers for more resources
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC (R)) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available